Antipsychotikaeffekt auf MR-Morphometrie und MR-Spektroskopie bei Schizophrenien

D. F. Braus; W. Weber-Fahr; S. Brassen

doi:10.1055/s-0038-1629947

Nervenheilkunde, Table of Contents

Nervenheilkunde 2005; 24(02): 105-112
DOI: 10.1055/s-0038-1629947

Original Article

Schattauer GmbH

Antipsychotikaeffekt auf MR-Morphometrie und MR-Spektroskopie bei Schizophrenien

Übersicht und eigene BefundeMR-Morphometry, MR-Spectroscopy and antipsychoticsReview and own data

Authors

D. F. Braus

¹NeuroImage Nord, Psychiatrie sowie Zentrum für Psychosoziale Medizin, Universitätsklinikum Hamburg-Eppendorf (Direktor: Prof. Dr. Dieter Naber)
W. Weber-Fahr

¹NeuroImage Nord, Psychiatrie sowie Zentrum für Psychosoziale Medizin, Universitätsklinikum Hamburg-Eppendorf (Direktor: Prof. Dr. Dieter Naber)
S. Brassen

¹NeuroImage Nord, Psychiatrie sowie Zentrum für Psychosoziale Medizin, Universitätsklinikum Hamburg-Eppendorf (Direktor: Prof. Dr. Dieter Naber)

Abstract

Zusammenfassung

Bildgebungsmethoden wie die MR-Morphometrie und die MR-Spektroskopie (MRS) werden seit längerem zur Untersuchung regionaler Hirnvolumen- bzw. -metabolismusveränderungen in der Schizophrenieforschung eingesetzt. Ein möglicher differenzieller Effekt von traditionellen Neuroleptika im Vergleich zu den atypischen Antipsychotika blieb dabei lange unberücksichtigt. In Übereinstimmung mit funktionellen Bildgebungsdaten zeigen nun neuere Daten, dass die so genannten atypischen Antipsychotika, verglichen mit traditionellen Neuroleptika, einen geringeren Einfluss auf die Basalganglienstruktur sowie einen eher günstigen Effekt auf die mit MRS gemessene neuronale Integrität zu haben scheinen. Das gilt ebenso für die Volumenveränderungen in fronto-temporalen Arealen sowie im anterioren Zingulum, welche mit kognitiven Funktionen korrelieren. Diese Befunde bedürfen jedoch vorsichtiger Interpretation, da die verbesserten Bildgebungsmöglichkeiten auch an zusätzliche methodologische Überlegungen geknüpft sind wie das Kontrollieren von Stör- und Moderatorvariablen, die exakte Designspezifikation, Strategien des Post-Processings, physiologische Variation des lebenden Gehirns, messbare Perfusionseffekte und Limitierungen durch die Hardware.

Summary

Recently there has been growing interest to employ neuroimaging tools such as MR morphometry and MR spectroscopy (MRS) to investigate regional brain volume change and metabolism associated with schizophrenia. The effect of different antipsychotic treatment on brain morphology and metabolism remains mostly unconsidered. More recently, in agreement with functional imaging data it could be shown that, compared to traditional neuroleptics, atypical drugs are less influencing basal ganglia structure and have a more favorable effect on neuronal viability in MRS and volume decrease fronto-temporal as well as in the anterior cingulated gyrus, correlating with cognitive function. These differential effects of antipsychotics need cautious interpretation since the improved imaging tools also give rise to additional methodological considerations such as control issues, specifications in experimental design, postprocessing strategies, physiological variation of the living brain, perfusion effects and hardware limitations.

Schlüsselwörter

MR-Morphometrie - MR-Spektroskopie - Schizophrenie - Antipsychotika

Keywords

MR morphometry - MR spectroscopy - schizophrenia - antipsychotics

Full Text

References

Literatur
1 Arango C, Breier A, McMahon R, Carpenter Jr WT, Buchanan RW. The relationship of clozapine and haloperidol treatment response to prefrontal, hippocampal, and caudate brain volumes. Am J Psychiatry 2003; 160: 1421-7.
2 Bertolino A, Caforio G, Blasi G, De Candia M, Latorre V, Petruzzella V, Altamura M, Nappi G, Papa S, Callicott JH, Mattay VS, Bellomo A, Scarabino T, Weinberger DR, Nardini M. Interaction of COMT Val108/158 Met Genotype and Olanzapine Treatment on Prefrontal Cortical Function in Patients With Schizophrenia. Am J Psychiatry 2004; 161: 1798-1805.
3 Bertolino A, Callicott JH, Elman I, Mattay VS, Tedeschi G, Frank JA, Breier A, Weinberger DR. Regionally specific neuronal pathology in untreated patients with schizophrenia: a proton magnetic resonance spectroscopic imaging study. Biol Psychiatry 1998; 43: 641-8.
4 Bertolino A, Callicott JH, Mattay VS, Weidenhammer KM, Rakow R, Egan MF, Weinberger DR. The effect of treatment with antipsychotic drugs on brain N-acetylaspartate measures in patients with schizophrenia. Biol Psychiatry 2001; 49: 39-46.
5 Bertolino A, Esposito G, Callicott JH, Mattay VS, Van Horn JD, Frank JA, Berman KF, Weinberger DR. Specific relationship between prefrontal neuronal N-acetylaspartate and activation of the working memory cortical network in schizophrenia. Am J Psychiatry 2000; 157: 26-33.
6 Braus DF, Brassen S, Demirakca T, Weimer E, Ruf M. Psychopharmakaeffekte und moderne Kernspintomographie: Stand der Diskussion, Möglichkeiten und Grenzen. Nervenheilkunde 2002; 21: 363-71.
7 Braus DF, Ende G, Weber-Fahr W, Demirakca T, Henn FA. Favorable effect on neuronal viability in the anterior cingulate gyrus due to long-term treatment with atypical antipsychotics: an MRSI study. Pharmacopsychiatry 2001; 34: 251-3.
8 Braus DF, Ende G, Weber-Fahr W, Demirakca T, Tost H, Henn FA. Functioning and neuronal viability of the anterior cingulate neurons following antipsychotic treatment: MR-spectroscopic imaging in chronic schizophrenia. Eur Neuropsychopharmacol 2002; 12: 145-52.
9 Carlsson A, Hansson LO, Waters N, Carlsson ML. Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci 1997; 61: 75-94.
10 Chakos MH, Lieberman JA, Alvir J, Bilder R, Ashtari M. Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. Lancet 1995; 345: 456-7.
11 Delamillieure P, Fernandez J, Constans JM, Brazo P, Benali K, Abadie P, Vasse T, Thibaut F, Courthéoux P, Petit M, Dollfus S. Proton magnetic resonance spectroscopy of the medial prefrontal cortex in patients with deficit schizophrenia: preliminary report. Am J Psychiatry 2000; 157: 641-3.
12 Ende G, Braus DF, Walter S, Weber-Fahr W, Soher B, Maudsley AA, Henn FA. Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia. Schizophr Res 2000; 41: 389-95.
13 Fannon D, Simmons A, Tennakoon L, O’Ceallaigh S, Sumich A, Doku V, Shew C, Sharma T. Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naive patients with schizophrenia. Biol Psychiatry 2003; 54: 587-98.
14 Gemperle AY, Enz A, Pozza MF, Luthi A, Olpe HR. Effects of clozapine, haloperidol and iloperidone on neurotransmission and synaptic plasticity in prefrontal cortex and their accumulation in brain tissue: an in vitro study. Neuroscience 2003; 117: 681-95.
15 Goff DC, Hennen J, Lyoo IK, Tsai G, Wald LL, Evins AE, Yurgelun-Todd DA, Renshaw PF. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry 2002; 51: 493-7.
16 Gur RE, Cowell P, Turetsky BI, Gallacher F, Cannon T, Bilker W, Gur RC. A follow-up magnetic resonance imaging study of schizophrenia. Relationship of neuroanatomical changes to clinical and neurobehavioral measures. Arch Gen Psychiatry 1998; 55: 145-52.
17 Ho BC, Andreasen NC, Nopoulos P, Arndt S, Magnotta V, Flaum M. Progressive structural brain abnormalities and their relationship to clinical outcome: a longitudinal magnetic resonance imaging study early in schizophrenia. Arch Gen Psychiatry 2003; 60: 585-94.
18 Job DE, Whalley HC, McConnell S, Glabus M, Johnstone EC, Lawrie SM. Voxel-based morphometry of grey matter densities in subjects at high risk of schizophrenia. Schizophr Res 2003; 64: 1-13.
19 Konradi C, Heckers S. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol Psychiatry 2001; 50: 729-42.
20 Lang DJ, Kopala LC, Vandorpe RA, Rui Q, Smith GN, Goghari VM, Lapointe JS, Honer WG. Reduced basal ganglia volumes after switching to olanzapine in chronically treated patients with schizophrenia. Am J Psychiatry 2004; 161: 1829-36.
21 Lee H, Tarazi FI, Chakos M, Wu H, Redmond M, Alvir JM, Kinon BJ, Bilder R, Creese I, Lieberman JA. Effects of chronic treatment with typical and atypical antipsychotic drugs on the rat striatum. Life Sci 1999; 64: 1595-1602.
22 Lieberman J, Charles HC, Sharma T, Zipursky R, Kahn R, Gur R, Tohen M, Green AI, McEvoy J, Perkins D, Hamer RM, Nemeroff C, Rothschild A, Kuldau J, Strakowski S, Tollefson GD. Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia. Schizophr Res 2003; 60 (Suppl. 01) 293.
23 Minami T, Nobuhara K, Okugawa G, Takase K, Yoshida T, Sawada S, Ha-Kawa S, Ikeda K, Kinoshita T. Diffusion tensor magnetic resonance imaging of disruption of regional white matter in schizophrenia. Neuropsychobiology 2003; 47: 141-5.
24 Schmitt A, Weber-Fahr W, Jatzko A, Tost H, Henn FA, Braus DF. Aktueller Überblick über strukturelle Magnetresonanztomographie bei Schizophrenie. Fortschr Neurol Psychiatr 2001; 69: 105-15.
25 Theberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RW, Rajakumar N, Schaefer B, Densmore M, Drost DJ. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 2003; 160: 2231-3.
26 Volz HP, Rossger G, Riehemann S, Hubner G, Maurer I, Wenda B, Rzanny R, Kaiser WA, Sauer H. Increase of phosphodiesters during neuroleptic treatment of schizophrenics: a longitudinal 31P-magnetic resonance spectroscopic study. Biol Psychiatry 1999; 45: 1221-5.